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ABSTRACT
This report summarises the presentations and activities of the ISEV Workshop on extracellular
vesicle biomarkers held in Birmingham, UK during December 2017. Among the key messages was
broad agreement about the importance of biospecimen science. Much greater attention needs to
be paid towards the provenance of collected samples. The workshop also highlighted clear gaps
in our knowledge about pre-analytical factors that alter extracellular vesicles (EVs). The future
utility of certified standards for credentialing of instruments and software, to analyse EV and for
tracking the influence of isolation steps on the structure and content of EVs were also discussed.
Several example studies were presented, demonstrating the potential utility for EVs in disease
diagnosis, prognosis, longitudinal serial testing and stratification of patients. The conclusion of
the workshop was that more effort focused on pre-analytical issues and benchmarking of
isolation methods is needed to strengthen collaborations and advance more effective biomarkers.
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Introduction
The potential utility for extracellular vesicles (EVs) as dis-
ease biomarkers has attracted unprecedented commercial
and academic interests over the last decade. The ability to
identify disease-related EVs within body fluids is compel-
ling for cancer, metabolic and cardiovascular disease, neu-
rodegenerative conditions and other disease syndromes.
However, the complexity of biofluids, competing technol-
ogies and the nano-scale nature of EVs present challenges
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that we need to face before EV biomarkers can be routinely
applied. We therefore held an ISEV workshop during 13–
14 December 2017, at the Medical School, University of
Birmingham, UK, to discuss critical issues, and to identify
potential approaches to enable better collaboration and
greater success in advancing effective biomarkers.
ISEVmembers submitted 73 abstracts, and 60 research-
ers were invited to contribute as presenters and/or in
round table discussions. Talks included plenary presenta-
tions from recognised EV research leaders and invited
perspectives from outside the EV realm. Selections took
account of gender, career stage balance and representation
from all geographical chapters, and the workshop was
structured from bench to bedside [1]: Pre-analytical vari-
ables, biobanking and vesicle isolation [2], discovery of EV
biomarkers [3], systems/assays to detect EV-markers
(rare event analyses) and [4] taking EV assays to the clinic.
We summarise presented viewpoints, achievements and
highlighted problems we face for developing EV-based
biomarkers (Figure 1).
General perspectives on biomarkers
Carolyn Compton from the (U.S.) National Biomarker
Development Alliance (NBDA) (Arizona State
University, USA) presented an excellent overview of
the biomarker field from outside the EV realm. For
21st century medicine, there is the expectation that the
molecular profiles of biospecimens will facilitate early
disease detection, diagnosis and personalised medicine.
Enabling technologies in the life sciences have drama-
tically increased assay sensitivity and evolved exponen-
tially, resulting in a “Tsunami of new data”, that allow
previously unimaginable deep-characterisation of biospe-
cimens, such as next-generation sequencing. As the
amount of data escalate, so do the challenges in handling,
analysing and understanding the arising datasets. We are
currently unclear about how we can fully capture this
information to aid the identification of biomarkers and
maximise their utility in clinical settings.
In marked contrast to the explosion of data generat-
ing tools, there remains a massive attrition in terms of
developing new therapeutics with on average 1:10,000
chance of success, which continues to be slow, typically
taking over 12 years, and costly, 2–5 billion USD, before
a final and approved marketable product is achieved. A
major reason for this slow and costly process is the lack
of validated biomarkers, highlighting the urgent need
for new technologies to address this need. Although
around 150,000 biomarkers have been claimed in the
scientific literature, the actual number of biomarkers
that are routinely used in clinical settings is only around
100 [1], although this figure may have changed since
2011. The NBDA has examined the principal deficien-
cies that have led to a general failure in biomarker
discovery and application, detailed in Table 1.
1. 
Isolation 
and pre-
analytics
2. 
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markers
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EV-
markers
4. EV-
markers in 
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negative predictive value
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linearity, dynamic range
• Understand issues impacting 
reproducibility
• Assay validation across 
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• Need for physical standards, 
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• Low cost / Rapid 
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Aims:
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Aims:
• Identification of disease-
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candidate(s), statistically 
informed.
Aims: Aims:
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provenance
• Preserve structural/molecular 
integrity of EVs
Notable Issues:Notable Issues:
• Need rigorous process 
management systems
• Multicentre studies with 
large numbers of patients
• Need better 
communication with 
regulatory bodies
Figure 1. Workshop topic areas and some highlighted problems.
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Medical sciences grossly suffer from a lack of scien-
tific reproducibility. For example, a recent study high-
lighted that of 53 studies published in high-impact
journals in oncology and haematology, only 11%
could be reproduced [3]. The actual extent of the
irreproducibility problem in biomedical research, in
general, and particularly in biomarker research is cur-
rently unknown and is under investigation. It is
expected to be significant because independent valida-
tion of research findings prior to publication is extre-
mely rare. Few biomedical researchers routinely
validate their findings in their own laboratories, and
even fewer seek external validation of their results in
independent laboratories. Importantly, from a biomar-
ker point of view, few studies attend to the quality and
consistency of human biospecimens that are the
sources of the analytes they are measuring and the
true foundation of all biomarker research efforts. The
implication being that the existing scientific literature
based on human biospecimen analysis is, at best, highly
problematic and likely reporting unreliable results.
Consequently, with such paucity of rigour in terms of
biospecimens collection and handling, it is no surprise
there is a general failure in biomarker discovery.
The modality of specimen collection has the capacity
to artificially alter the molecular integrity and/or the
composition of biospecimens, thereby changing the
analysis data. Thus, pre-analytical variables have the
capacity to exert a major impact on all subsequent
information being gathered from the biospecimen and
artefactually alter multiple types of analysis data. For
example, there are numerous reports of collection,
processing and handling variables that affect the com-
position of blood and serum. Many of these have been
demonstrated to have a significant impact on EV ana-
lysis. Unfortunately, the list of pre-analytical variables
is long, and includes at least 17 process-related factors
that may affect analysis data (Table 2). In addition,
there are numerous donor-related variables including
age, body mass systemic disorders, etc. about which
very little is currently known.
In many studies, such specific details are not consid-
ered, controlled or reported, and hence it is impossible to
accrue sufficient evidence to develop optimised standard
operating procedures (SOPs) when both analytes and
analysis are variable. The study results take centre stage,
and pre-analytical details, compliance with protocols and
the management of adherence to these are rarely dealt
with in a suitably rigorous fashion. In 2013, ISEV pub-
lished a position paper to create awareness on the impact
of pre-analytical variables on EV analysis in body fluids
[10]. Recently, the EV-TRACK consortium created a plat-
form (www.evtrack.org) to improve the transparency and
compliance in reporting such parameters with the aim to
increase reproducibility of EV research, a prerequisite to
initiate EV biomarker [11].
Taken together, rigorous biospecimen research is
urgently needed to boost the quality of medical
sciences in general, and a prerequisite to implement
EV-based biomarkers into the clinics. To achieve this
goal, SOPs regarding biospecimen collection and hand-
ling must be developed as a sound basis for future EV
research.
General perspectives on EV biomarkers
Raghu Kalluri (UT MD Anderson Cancer Center,
Houston, USA) showed the potential value of EV-
associated DNA. EVs from several human and mur-
ine cancer lines contain fragments of genomic DNA,
up to 19 kb long and DNase resistant, suggesting an
intraluminal encapsulation of the DNA. It clearly
established now that the DNA is double stranded
and can also be in the single-stranded form. In
plasma, most genomic DNA was associated to EVs,
and genetic profiling (of EVs) identified tumour-
related mutations such as KRAS in pancreatic cancer
patients [12]. Importantly, regarding tumour hetero-
geneity the mutational profile of biopsies from dis-
tinct sites within a patient can differ. Sampling
circulating EVs, however, potentially captures all
such mutations from a single biospecimen, providing
a more complete picture of genomic aberrations.
Table 1. NBDA top ten reasons for the failure in developing
effective biomarkers [2].
1 Poor access to rigorously annotated, fit-for-purpose biospecimens
from stringently phenotyped sources
2 Insufficient control of pre-analytical parameters
3 Low reproducibility of academic publications
4 Incomplete understanding of physiology
5 Variable analytical standards
6 Idiosyncratic laboratory-specific analytical methods
7 Small studies lacking statistical power
8 Chaotic data reporting formats and poor database interoperability
9 Poor compliance on reporting standards by scientific journals
10 Poor to non-existent quality management systems
Table 2. Factors relevant for biospecimen variability during
blood collection/handling/storage.
1. Tourniquet vs. none 2. Tourniquet time
3. Central line or artery vs. peripheral vein 4. Draw order
5. Temperature and duration of storage 6. Tube type
7. Tube volumea 8. Tube inversions
9. Vacuum tube, butterfly vs. syringea 10. Type of anticoagulant
11. Type of port (if used for access) 12. Total time of draw
13. Number of centrifugationsa 14. Needle bore
15. Time to centrifugationa 16. Centrifuge speeda
17. Tube agitation during transporta
a Indicates where data exist for impact on EVs [4–10].
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Because healthy individuals also exhibited such muta-
tions in their serum EV-associated DNA, this
approach may also predict potential propensity
towards developing cancer but with cautionary note
that mutation detection does not guarantee develop-
ment of clinical disease of cancer.
EVs with glypican-1 on their surface were previously
identified as a biomarker for pancreatic cancer [13].
Since this publication, several different laboratories
have validated the concept that glypican-1 is enriched
on the EVs derived from cancer cells [14].
Additionally, multiple antibodies have been identified
that can recognise glypican-1 on the surface of cancer
exosomes [15], and validation studies are currently
underway.
These example studies identify broad perspectives
for EV utility in cancer as a multiplex set of molecules
that inform us about disease status and likely hold
predictive value. They also reiterate the importance of
analytical methods, and the details therein and an
important role for inter-lab validation of such discov-
eries prior to future evolution towards clinical
application.
Workshop topic 1. EV Isolation and pre-analytical
considerations
Rienk Nieuwland (University of Amsterdam,
Netherlands) showed that blood contains all blood clot-
ting components apart from one essential component.
This is a transmembrane protein, tissue factor (TF),
which activates coagulation factor VII to factor VIIa,
and thereby triggers the clotting of blood. In physiological
conditions, TF is abundantly present on EVs in normal
human saliva (and other body fluids such as urine and
lacrima), and the ability of EVs from saliva to trigger
blood clotting is comparable to snake venom [16].
However, TF-EVs can also be present within per-
ipheral blood, and in various types of cancer, TF-EVs
released from the tumour are thought to increase the
risk of developing venous thromboembolism (VTE).
Recently, a prospective multicentre trial of almost 900
cancer patients was completed to predict VTE using
four predication scores [17]. The main conclusion was
that none of these scores can be used to identify
patients at risk of VTE. But in a subgroup of 650 cancer
patients the ability of an EV-based clotting test, the
fibrin generation test (FTG), to identify cancer patients
at risk of developing VTE was examined. This assay
outperformed current predictive models pancreatic
cancer patients (n = 100). During the study, however,
knowledge of blood handling/collection has evolved
and the FGT test is amenable to great improvements
[18]. Taken together, given the fact that each year
about 10,000,000 new cases of VTE are described, of
which 20% are associated with cancer, further explor-
ing the coagulant properties of EVs to predict VTE in
certain types of cancer, is promising.
Cecilia Lässer (University of Gothenburg, Sweden)
addressed the problem of isolating EVs from 0.5–1 mL
of plasma/serum, and to separate EVs from lipopro-
teins and chylomicrons. Lipoprotein particles such as
LDL, HDL and chylomicrons resemble EVs when it
comes to size and/or density and it can therefore be
hard to isolate pure EVs from blood. By combining
separation based on density, using an iodixanol cush-
ion, followed by separation based on size, by size exclu-
sion chromatography (SEC), effective isolation of EVs
well separated from lipoprotein particles was achieved.
This approach also revealed that the majority of events
observed in plasma, by techniques such as NTA is most
likely lipoprotein particles and not EVs, highlighting
the hurdles working with complex clinical samples
[19]. A similar approach was described by An
Hendrix (Ghent University, Belgium), except reversing
the order with SEC followed by density gradient cen-
trifugation. Processing plasma/serum in this fashion is
effective but laborious, however, and a more tractable
approach would be needed to handle large sample
numbers. As patient specimens are precious and often
of limited volumes, adapting isolation and/or analysis
techniques for small-volume biofluid samples will
likely aid in moving EV biomarker candidates into
the clinics.
Lesley Cheng (La Trobe University, Australia) empha-
sised the relevance of pre-analytical standardisation of
blood and urine sample collection and handling on EVs,
in particular for isolation of EV-associatedmicro (mi)RNA
[20]. Importantly, even when the effect of pre-analytical
variables on the sample are unknown, consistency and
compliance with downstream SOPs is extremely important
to enable the comparison of results between collected
samples. For blood collection, the effects of pre-analytical
variables and cofounders were discussed, such as the effect
of haemolysis, and the preferential use of fasting blood
samples [21]. For collection of urine samples, the value of
adding protease inhibitors and reducing agents were dis-
cussed. For downstreamRNA-extraction, a variety of com-
mercial kits was compared, and despite the limitations of
such kits the obtained results may be more consistent than
traditional ultracentrifugation-based isolation approaches.
Luca Musante (University of Virginia, USA) also
presented data on urine collection, preferring first
morning urine for collection, and demonstrating that
a citrate-based buffer is beneficial in controlling pH
and reducing precipitates after thawing, although this
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may affect size and composition of EVs. Improved
control of inter-day variation with regards to EV recov-
ery, was achieved in the presence of protease inhibitors,
but the optimal inhibitor cocktail remains unresolved.
It was shown that two different protease inhibitor
cocktails had different impacts on the ratio of Tamm-
Horsfall protein (THP) polymerisation and yield of
both THP and urinary EVs in the centrifugation pel-
lets. Reducing agents to breakdown THP polymers and
protein aggregates was viewed as advantageous for EV
recovery but still minimal variation of the experimental
condition such as pH, presence or absence of protease
inhibitors can dramatically influence the repartition of
EVs and THP in the pellet and supernatant, respec-
tively. However, the physical associations between EVs
and THP remains ill defined, and perhaps is an aspect
deserving of greater attention.
There is a need of experimental standards to moni-
tor the efficacy of EV-protecting steps and isolation
procedures. Being able to spike-in reference EVs, EV-
like particles or an artificially synthesised EV mimic
was thought to be a valuable approach to identify
critical variables in collection, storage and handling of
EV-containing samples. An Hendrix described ongoing
studies to manufacture an EV-like standard, which is
endogenously fluorescent, thus allowing analysis by
multiple platforms. Likely, the field may require an
assortment of standards, depending on the measure-
ment-platform. The use of artificial EV standards is
likely to facilitate the development of evidence-based
SOPs for collection, storage and handling of EVs.
Unfortunately, many researchers need to rely on bios-
pecimens from established bio-banking organisations, in
which the methods for collection, handling and storage
were not intended for EV research. Ryan Pink (Oxford
Brookes, UK) highlighted a potential opportunity, invol-
ving a UK national initiative. The UK Biobank
Consortium, which has been collecting specimens from
500,000 healthy individuals over the last 11 years. The
specimens are well annotated, with information on life-
style, physiology, blood biochemistry and genomics, and
about 200,000 individual whole-body MRI scans.
Critically, this data is linked to full health records within
the UK’s National Health Service, thus offering a com-
prehensive set of materials and metadata currently
untapped for EV studies. However, the release of speci-
mens will be limited in terms of quantity, that is no more
than 0.5 mL per individual, and hence our methods for
isolation and profiling of EVs need to be compatible with
this level of input material. Ryan presented work and
discussion on extracting EVs from 50 µl of plasma, the
effect of freezing and collecting functional RNA and
protein, making small biobank sample use more realistic.
Nevertheless, there are opportunities for EV researchers
to exploit biobanks, and to integrate EV-profiling infor-
mation with other available information.
Workshop topic 2. Profiling EVs from biofluids
Takahiro Ochiya (National Cancer Center Research
Institute, Tokyo, Japan) presented a plenary overview
of the value of EV profiling in disease, concentrating
on an $80 million study to develop miRNA-based
technologies for disease diagnoses.
On average, 37% of blood-borne miRNA is present
within EVs, and three miRNAs were identified, miR-
149-3p, 2861 and 4463, that are consistently present in
all serum samples, and which potentially provide an
internal normalisation control. The team profiled vesi-
cular miRNA across a spectrum of cancer types,
dementia and healthy individuals, accumulating data
on over 42,000 individuals. The data were processed by
Fishers linear discriminant analysis, in an iterative
fashion to identify combinations of candidate
miRNAs capable to discriminate health from disease.
Many successes of this approach were shown, revealing
the extraordinary capacity to diagnose colon cancers
using a set of 5 miRNAs with >95% sensitivity and
specificity, and similar findings were shown for com-
mon cancers such as lung, brain and pancreas cancer.
Results using the ExoScreen assay from the same
group [22] showed that detection of CD145/CD9 dual
positive cancer EVs is possible using 5 µL serum of
colorectal cancer patients, and that EVs positive for
GPRC5C/CD63 can discriminate pancreatitis patients
from stage II pancreatic cancer. The assay is flexible for
other cancer types also and examples of other cancer
site-specific bead pairs were presented. There is there-
fore proven value in examining vesicles in terms of
profiling their microRNA, and computational tools
will allow optimised biomarker sets to be revealed,
and subsequently tested for their diagnostic power.
Juan Manuel Falcon-Perez Perez (CIC bioGUNE,
Derio, Spain) highlighted the ongoing revolution in EV
research and application. The utility of circulating EVs to
assess liver injury was illustrated, showing that alterations
in the hepatocyte proteome are partly reflected by the
proteome of EVs, thus offering an alternative for liver
biopsy. Interestingly, liver injury often leads to changes in
liver-specific enzymes, and these remain catalytically
active when released within EVs. Addition of hepatocyte
EVs to serum results in a host of newmetabolites, such as
ornithine, due to the catalytic activities of EV-associated
arginase [23]. Hence, the assessment of liver injury can be
inferred from profiling EVs and the repertoire of meta-
bolites within biofluids [24].
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There were several presentations from Juan Manuel
Falcon-Perez, Alicia Llorente (Oslo University
Hospital, Norway), and Elena Martens-Uzunova
(Erasmus MC, Rotterdam, Netherlands) about prostate
cancer, using urine as a source of EVs. They showed
promising data where EV proteins such as CD10 and
Flt1 could discriminate enlarged yet benign prostatic
hyperplasia from genuine prostate cancer. Also, there
were examples of EV-associated messenger RNA and
microRNA, e.g. CDH3, or miR-196a-5p, being consis-
tently downregulated in prostate cancer, and examples
of other types of small noncoding RNA such as
snoRNA and tRNA detectable in EVs. However, the
detection of some of these markers critically depends
on the sample processing methodology in terms of
both EV capture and RNA extraction, where different
commercial kits show enormous differences in RNA
yield and quality suitable for downstream applications.
In quite a different disease setting, Metka Lenassi
(University of Ljubljana, Slovenia) showed that HIV
patients who are apparently virus free, may encounter
non-AIDS-related disorders, such as inflammatory-
related complications [25]. The utility of EVs was
explored to identify potential active HIV reservoirs
in aviremic individuals. EVs were isolated from
plasma by sucrose cushion/centrifugation that effi-
ciently removes LDL and chylomicrons. With these
specimens, the HIV-encoded protein Nef was
detected in half of aviremic patients by ELISA. Nef
levels associated with the antiretroviral therapy
(ART) regimen, but did not correlate with clinical
characteristics [26]. Additionally, the profiling of
vesicular miRNAs discovered miR-20a and miR-223,
showing greater potential, and which correlated with
CD4/CD8 T cell ratios. Thus, there is utility in cir-
culating EVs to determine the presence of active HIV
reservoirs that may be drivers of co-morbidities even
in the absence of infectious HIV virus.
In summary, profiling the complex components of
EVs, or EV-induced metabolites hold direct promise as
disease indicators across a variety of clinical situations,
and clearly highlight a need for more expansive efforts
for fine-tuning of biofluid storage and handling meth-
ods, during the important validation of these identified
markers that must follow.
Workshop topic 3. Assays for EV-based markers
and rare event analysis
The capacity to identify EV-associated biomarkers in a
simple, rapid and cost-effective manner will be a cri-
tical step in the development of EV-based biomarkers,
and hence the workshop explored some of the potential
methodologies to achieve this. Amongst the accepted
technologies widely utilised is that of flow cytometry,
and Marca Wauben (Utrecht University, Netherlands)
presented an overview of the advantages and difficul-
ties of this technology for analysis of EVs.
Critically, flow cytometers were not designed for
detection of submicron sized particles, e.g. EVs, and
traditional instruments remain limited in their capacity
to discriminate EVs from instrument noise. The major
issue of multiple small particles providing a single detect-
able event and how sample dilution can prevent such
“swarming” effects, was discussed [27]. Swarm artefacts
are also problematic in terms of multi-colour fluorescent
labelling and false-positive events. Nevertheless, it is pos-
sible to detect rare sub-populations of EVs, 0.01–0.1% of
all EVs present, with a well setup instrument and know-
ing the limitations of the instrument.
To improve the quality of flow cytometric analyses
of EVs, an ISEV-ISAC-ISTH EV-Flow cytometry work-
ing group is working on consensus of methods, stan-
dards and consistent reporting. With respect to
reporting, currently most scientific journals do not set
criteria regarding flow cytometry experiments, and the
working group is preparing a checklist of the most
critical details for submission with flow-derived data
sets on EVs. Key to the future development of single
EV-based flow cytometry would be the involvement of
manufacturers in terms of instrumentation design tai-
lored towards EVs. Also, development of calibration
beads in the EV size-range and with dim fluorescence
as well as reference material with similar physical-che-
mical properties as EVs are needed.
Joshua Welsh (National Cancer Institute, NIH
Bethesda, USA) used flow cytometry of EVs in clinical
studies of liver fibrosis, where staining for leukocyte
markers on EVs reflected the severity of fibrosis and
liver function. Details of why flow cytometer set-up
information, gating strategy and the use molecules of
equivalent soluble fluorophore (MESF) reference beads
and particle scatter modelling were needed for the
reporting of EVs in translational studies was explained.
The software to convert arbitrary fluorescence units to
MESF-units is freely available for FlowJo (http://www.
joshuawelsh.co.uk/flowjo-mesf-calculator/), and aids in
quantifying aspects such as ligand density on single
EVs. Similarly, free software will become available to
calculate the EV diameter from light scatter, which
should help the community in comparing data between
instrument platforms, and help drive improved inter-
operability, and validation across laboratories.
Carina Levin (Emek MC, Haifa, Israel) discussed the
possible utility of EVs as a marker of β-thalassemia
major. As well as observing elevations in numbers
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and size of EVs by nanoparticle tracking analysis, ele-
vated levels of intra-vesicular HSP70 were apparent,
which correlated with erythropoiesis and haemolysis
parameters.
Benedikt Kirchner (Technical University of Munich,
Germany) highlighted that isoforms of miRNA
(isomiRs) are rarely examined, yet these may provide
useful biomarker utility. Developed tools for isomiR
reference file generation and isomiR read count analy-
sis were shown and applied in a study on EVs in
clinical depression. Using small RNA sequencing of
blood-derived EVs, isomiR analysis increased the
robustness of the signal, improving mapping and clas-
sification, and 300% more differentially expressed tran-
scripts compared to classical analysis approaches. This
analysis can be added to existing datasets/pipelines,
and can reveal differences in control, moderate and
severely depressed individuals that may not be appar-
ent using traditional tools. These are examples where
already-available technology can be adapted for utility
in EV measurements and analysis, and reveal biomar-
ker features in different disease settings.
Yoon Kang (Korea Institute of Science and
Technology, Seoul, South Korea) used antibody-coated
magnetic beads to assess EV-surface proteins, followed
by an impedance measurement, configured as a micro-
well sensor-array [28], to determine ligand binding.
This provides a highly sensitive modality for antigen
detection, of <1 pg/ml, outperforming ELISA-like plat-
forms. The assay was applied to assess plasma-derived
vesicular amyloid β42 in Alzheimer disease, and was
capable of identifying late-onset patients compared to
controls. This is an example that new EV-detection
technology is rapidly evolving, showing good potential
enhancement of detection sensitivities with clinical
biofluids.
Similarly, George Daaboul (nanoView Diagnostics,
Boston, USA, sponsored presentation) discussed affi-
nity immobilisation of EVs on a microarray printed on
an engineered chip surface to allow interferometricly
enhanced imaging of single vesicles. The instrument
requires low input material, 5–100 μL, and provides a
label-free size distribution of subpopulations of affinity
captured EVs. Although the throughput is currently
limited, the platform may present an alternative to
flow cytometry for small EVs down to 40 nm. A helpful
technology presentation from Clemens Helmbrecht
(Particle Metrix GmbH, Meerbusch, Germany; spon-
sored presentation) described the varied uses of the
ZetaView technology in particle sizing, counting and
showcased fluorescence and charge-based analyses cap-
abilities of the instrument. In particular, the presenta-
tion indicated the awareness of manufacturers of the
need for rigour in vesicle analysis, and how factors
responsible for variance in the analysis platform can
be understood, and minimised.
Workshop topic 4. Taking EV markers to the clinic
The sample collection processing and assay systems are
leading towards real-world utility in clinical settings
and there were several successful examples presented
pointing to genuine relevance of EVs as clinically use-
ful. A plenary by Jennifer Jones (National Cancer
Institute, NIH Bethesda, USA), centred on the ambi-
tion to use EVs for personalised medicine, and high-
lighted that the typical intervals between treatment
initiation and measurement of treatment responses
span many months, whereas biological effects of treat-
ments are known to occur within days to weeks. Since
EVs are released continuously by cells and since those
EVs carry biomolecular signatures that reflect the state
of the cells that produce them, early post-treatment EV
analysis opens a possible window for identification of
responses to treatment. Ultimately, it is hoped that
early EV analysis may provide a means to determine
when treatments are not working and could be
adjusted for therapeutic benefit.
Various forms of flow cytometry approaches were
presented, including a recent nano-flow (nanoFCM)
platform developed by Xiaomei Yan’s laboratory at
Xiamen University. This gives superior light scatter-
based resolution down into the 40 nm range [29] and
single-fluorescent molecule detection and demon-
strated identifying EV populations stained for epithelial
cell adhesion molecule (EpCAM), prostate-specific
membrane antigen (PSMA) and CD147. This next-
generation instrument is capable of providing accurate
EV concentrations for a specific phenotype, and this
quantitation is what clinical laboratories require. Yet
this next-generation technology in its current imple-
mentation is slow, with sample preparation that is
labour intensive and requires research lab- rather
than clinical lab-compatible instrumentation to reduce
residual fluorophore and other artefacts. Nevertheless,
nano-flow sorting offers great potential for detailed
sub-population profiling for miRNA content for exam-
ple, and data of this approach are now emerging from
the clinic. Alternative coupling of vesicles to beads,
using multiplex bead sets developed by Miltenyi was
described, showing improved, multiparametric pheno-
typic analysis of vesicle subsets than can be achieved
with single vesicle cytometric methods. Multiplex ana-
lysis also may provide a useful approach to elucidate
some of the confounding variables previously discussed
around sample collection revealing the loss of certain
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EV populations dependant on blood tube type, antic-
oagulant used, etc. There was agreement that issues
surrounding collection are highly impactful.
Hidetoshi Tahara (Department of Cellular and
Molecular Biology, Hiroshima University, Japan)
described the role of miR-22 in regulating cellular
senescence, and its application to induce senescence
in breast cancer, perturbing growth and metastatic
spread. Using a functional high-throughput screening
system of senescence-inducible microRNAs, new
senescence-associated miRNAs were identified, includ-
ing one which exhibited high potency in the resolution
of tumours in preclinical models. Screening serum or
plasma EVs showed some disagreement in the miRNA
with more t-RFs (tRNA fragments) in serum, but
appeared to be sensitive to detect very small solid
cancers (of 5 mm). The study of iso-miRs within such
datasets was more informative comparing disease ver-
sus controls, than the study of mature miRNAs using
an optimised SOP for microRNA analysis from blood.
Such analyses were possible with little input material
(200 μl), and are therefore likely very compatible with
clinical situations.
J. Brian Byrd (University of Michigan, Ann Arbor,
USA) stated an unmet need for biomarkers of miner-
alocortacoid receptor (MR) activation, and questioned
whether transcriptional activity (downstream of MR
activation) could be detected in urine as a surrogate
of MR activity. He described findings from a crossover
study of participants with prehypertension who con-
sumed a low-sodium diet and subsequently underwent
sodium loading. Potential target transcripts such as
those encoding subunits of the amiloride-sensitive
epithelial sodium channel and others, were shown to
change with sodium loading. In addition, these tran-
scripts correlated directly with serum aldosterone con-
centrations and inversely with excreted urinary
sodium.
Dakota Gustafson (University of Toronto, Canada)
discussed relationships between end-stage renal dis-
ease, cardiovascular mortality and the current lack of
appropriate clinical markers to identify patients at the
highest risk of adverse cardiac events. Using high-
throughput microfluidic-based qRT PCR on 600
patient plasma-derived EVs he described how miR-
125b, miR-23-3p, and miR-124 were identified as pos-
sible cardiovascular disease biomarkers and the utility
of microfluidics-based EV analysis in the clinic.
Additionally emphasised was the clinical overlap
between heterogeneous patient groups, in particular
those with multiple co-morbidities, and the growing
requirement for combinatorial miRNA biomarker
panels for robust clinical discrimination.
Andreas Möller (QIMR Berghofer Medical Research
Institute, Herston, Australia) described a difficult clin-
ical situation in non-small cell lung cancer (NSCLC),
where current pathological testing is insufficient to
determine if early-stage patients should undergo thera-
pies in addition to surgery. An assay system was pre-
sented, based on the detection of altered protein
composition in EVs from transformed NSCLC cells
[30]. This might provide a novel biomarker for rational
clinical decision-making, stratifying those NSCLC
patients most likely to benefit from additional therapies.
Andrew Hoffman (Cummings School of
Veterinary Medicine, Tufts University, North
Grafton, USA) showcased models from veterinary
medicine, highlighting how lessons learned in large
mammals (e.g. canine) can equally be applied to
patients, particularly as many diseases show striking
commonalities with human diseases. Canine mitral
valve disease, a model of human mitral valve prolapse
and outright prevalent problem in veterinary medi-
cine lacks biomarkers. Studies were presented show-
ing that EV RNA isolation using a commercial
isolation kit, exoRNeasy, required 4-fold less plasma
volume and shows significantly less variability with
low copy number miRNAs compared to ultracentri-
fugation methods. However, some challenges exist in
novel species, where RNAseq data may annotate only
well-conserved features. Further, for small animals
low volumes of plasma or serum (<0.1 ml) may
compel advances in low input isolation, library pre-
paration, sequencing and bioinformatics.
Workshop take-home messages and future
perspectives
The workshop highlighted many exciting areas of EV
biomarker research which fully showcase the potential
of this field to make a genuine impact on disease
identification, predicting disease, tracking responses
to therapeutic intervention and personalised medicine.
There was a mixture of large replicative studies as well
as promising smaller-scale investigations across a vari-
ety of disease types.
Among the most prominent issues however was that
of the biospecimen, its full provenance, the details of its
donor characteristics, environment, collection, storage,
transportation and handling prior to arrival at the
laboratory for EV analysis. The adage of trash-in
equals-trash-out is certainly an issue that should be
high on our collective agendas.
Whilst many bio-banking resources have well-estab-
lished processes for the collection and generation of
specimens such as serum/plasma, these protocols have
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not been developed to consider the preservation of the
structural and molecular integrity of EVs and down-
stream manipulations. It may well be that many of
these routinely used by potentially enormous resources,
such as the UK Biobank highlighted by Ryan Pink,
have a specimen collection that is reasonably compa-
tible with EV studies. If so, this creates many opportu-
nities to define EVs in a normal healthy ageing
population as a reference for comparisons with disease
subjects. Currently, however, there is a knowledge gap
about the variables impacting EVs, and our abilities to
perform critical specimen quality assessments prior to
embarking on EV investigations.
Collection of blood will introduce peculiar variables
compared to urine, cerebrospinal fluid, saliva, milk or
other fluids, and as such each type of biofluid brings a
new set of unknowns in terms of sample handling.
Furthermore, downstream applications will be sensitive
to these upstream procedures, such as the use of
Polyethylene Glycol precipitants potentially causing
issues with mass-spectrometric analyses; this further
confounds the development of a single robust sample-
handling procedure that suits every need.
How might we identify the parameters that do not
have a big effect on EVs and those that indeed do
impact EV integrity? It is unlikely for most funding
agencies to find a research proposal of this nature
sufficiently exciting to warrant investment; yet it is
clearly an area which could have enormous future
impact. Many studies, in this workshop and published
works, have begun to address such questions. It would
be useful at this point to collect what is already known
to impact features of biofluid EVs (e.g. count, size,
integrity, composition and activity), and to identify
what consensus exists within our community on such
variables, and describe the best practice methods as far
as we currently conceive. Value may be gained by
scoping other disciplines, such as pharmaceutical lipo-
somes for example and how their presence in biofluids
can be maximally preserved. Perhaps, collectively as
researchers, we must pay more attention to our labora-
tory processes, to manage the adherence to SOPs, and
to fully document in explicit fashion the details of each
step. Usage of EV-TRACK [11] and compliance to the
MISEV (minimal requirements for reporting EV-
mediated effects) [31] guidelines is encouraged. It is
likely that the sharing of quality and well-considered
SOPs, even in a background of incomplete knowledge,
will immediately aid reproducibility, and allow cross-
validation of discoveries to be more successful.
Many delegates agreed that having an ability to
physically trace EVs during sample storage/handling
procedures would be enormously useful as a tool to
hone SOPs. Their nano-scale size makes protocol
development difficult because they are so difficult to
detect. The idea of a reference EV, EV-like particle or
an artificial vesicle-mimic that is fully standardised in
terms of numbers/size, etc., perhaps carrying a fluor-
escent marker was proposed as a means of achieving
this kind of quality control. It requires some detailed
considerations, however, as the heterogeneity and com-
plexity of EVs will be impossible to fully reflect by an
EV reference or artificially prepared EV mimic.
Furthermore, we need different types of standards for
different applications. Nevertheless, standards includ-
ing dim-fluorescent beads to aid flow cytometry set up,
and facilitate the inter-lab validation of procedures and
discoveries will undoubtedly be a forward step in this
field. The involvement of companies, with technologies
in place to design and certify such standards is likely to
accelerate such developments. Similarly, academic
researchers and ISEV should collaborate closely with
manufacturers, biotechnology companies and regula-
tory agencies to refine current instruments for EV
analysis and to translate EV-based biomarkers into
marketable products.
The development of assay systems to measure EVs
is an area of rapid growth, both with established
platforms like flow cytometry undergoing an evolu-
tion towards nano-scale resolution, or other up and
coming micro-fluidic/chip array platforms. The fac-
tors to consider with all such instrumentation, how-
ever, is knowing the mechanism of the platform and
its limitations, as without this understanding the data
arising may be misinterpreted. Additionally research-
ers should be aware of input parameters (volumes,
buffers and viscosities), limits of detection, linearity,
dynamic range, performance time and confounding
factors in biofluids that can skew results. Researchers
should know the inherent reproducibility and meth-
ods of quality control and assurance of the instru-
ment. Validation of rare events could include
labelling with different reagents, the use of other
complementary assay systems, and to include a
spike-in positive control ensuring suitable detection.
The presence of nano-aggregates in fluids may pro-
vide a signal that is not genuinely related to EVs, and
discussions around detergent lysis of EVs may help
clarify ambiguities here.
In summary, this ISEV workshop has been a wake-up
call for educating EV researchers about the real-world
difficulties of biomarker discovery and application.
However, we trust sharing information about successes
and common confounders in this fashion is a spur for
future efforts to overcome, and to bolster the major
problem of scientific rigour, reproducibility and
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transparency that we all face. Funding agencies should
also be aware of the enormous socio-economic benefits
that EVs research could have for society in general and
foster multicentre projects to help to overcome the above
mentioned issues. Work groups have been tasked now
that will build further on the ISEV position paper on pre-
analytical variables [10] with examining in detail what is
currently known about pre-analytical variables in relation
to blood, urine and other biological fluids. In addition,
ISEV will begin the implementation of a standardisation
committee in order to fuel accelerated activities, and to
progress these aspects of the EV field.
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